BusinessOcera Therapeutics Selected to Present an Oral Presentation and Three Posters on OCR-002 at the AASLD Liver Meeting® 2017By Nasdaq OMXAug 23, 2017, 1:05 PM UTC
BusinessOcera Therapeutics to Host KOL Conference Call on Hepatic Encephalopathy and Other Complications of Liver Disease on Friday, June 2By Nasdaq OMXMay 26, 2017, 1:05 PM UTC
BusinessOcera Therapeutics Reports First Quarter 2017 Financial Results and Provides Clinical UpdateBy Nasdaq OMXMay 9, 2017, 8:09 PM UTC
BusinessOcera Therapeutics Reports First Quarter 2017 Financial Results and Provides Clinical UpdateBy Nasdaq OMXMay 9, 2017, 8:09 PM UTC
BusinessOcera Therapeutics Reports First Quarter 2017 Financial Results and Provides Clinical UpdateBy Nasdaq OMXMay 9, 2017, 8:09 PM UTC
BusinessOcera Therapeutics Reports First Quarter 2017 Financial Results and Provides Clinical UpdateBy Nasdaq OMXMay 9, 2017, 8:09 PM UTC
BusinessOcera Therapeutics to Report First Quarter 2017 Financial Results and Provide Clinical Update on May 9, 2017By Nasdaq OMXMay 3, 2017, 8:05 PM UTC
BusinessOcera Therapeutics Announces Presentation of Data Showing OCR-002 Prevented Progression of Fibrosis in Preclinical Model of Non-alcoholic Fatty Liver Disease (NAFLD)By Nasdaq OMXApr 12, 2017, 8:08 PM UTC
